ArticleChemistry (Weinheim an der Bergstrasse, Germany)2020
Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions.Biotechnology and bioengineering · 2026Article
- Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms.Angewandte Chemie (International ed. in English) · 2025Article
- Selective Phosphorylation of Phenols and Benzenediols by the Kinase PsiK and Variants Thereof.Angewandte Chemie (International ed. in English) · 2025Article
- In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters.Scientific reports · 2025Article
- The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Structural basis for psilocybin biosynthesis.Nature communications · 2025Article
- Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.FEBS letters · 2025Article
- Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.Molecular biotechnology · 2025Review
- Methyl transfer in psilocybin biosynthesis.Nature communications · 2024Article
- Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents.Biomedicines · 2023Review
- A Review of Synthetic Access to Therapeutic Compounds Extracted fromPharmaceuticals (Basel, Switzerland) · 2022Review
- Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis inJournal of fungi (Basel, Switzerland) · 2022Article
- Genetic Survey of Psilocybe Natural Products.Chembiochem : a European journal of chemical biology · 2022Article
- Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines.Chembiochem : a European journal of chemical biology · 2022Article
- The Therapeutic Potential of Psilocybin.Molecules (Basel, Switzerland) · 2021Review
- Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.Journal of natural products · 2021Article
- Review
- A draft reference assembly of theF1000Research · 2021Article
- Psilocybin: from ancient magic to modern medicine.The Journal of antibiotics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Psilocybin, the principal indole alkaloid of Psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment-resistant depression and major depressive disorder. The psilocybin supply for pharmaceutical purposes is met by synthetic chemistry. We replaced the problematic phosphorylation step during synthesis with the mushroom kinase PsiK. This enzyme was biochemically characterized and used to produce one gram of psilocybin from psilocin within 20 minutes. We also describe a pilot-scale protocol for recombinant PsiK that yielded 150 mg enzyme in active and soluble form. Our work consolidates the simplicity of tryptamine chemistry with the specificity and selectivity of enzymatic catalysis and helps provide access to an important drug at potentially reasonable cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.